Bio Medica Laboratories IPO
Bio Medica Laboratories IPO is a book built issue of ₹37,72,000 crores. The issue is a combination of a fresh issue and an offer for sale. The subscription opens on 21 May '26 and closes on 25 May '26, with the basis of allotment expected to be finalised on 26 May '26. The shares are scheduled to list on NSE. The price band is set at ₹132 to ₹139 per share with a minimum lot size of 1,000 shares. Narnolia Financial Services Ltd is the book-running lead manager, while Skyline Financial Services Pvt.Ltd. is the registrar of the issue; for detailed information, refer directly to the official Bio Medica Laboratories IPO RHP.
Free Demat with Zero AMC*
Bio Medica Laboratories IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 1% | 37,720 crores |
| Non-Institutional Investors (NIIs) | 48% | 18,10,560 crores |
| Retail Individual Investors (RIIs) | 51% | 19,23,720 crores |
About Bio Medica Laboratories Ltd IPO
Bio Medica Laboratories Ltd. (BMLL), incorporated in 2015, is a pharmaceutical manufacturing company based in Madhya Pradesh, focused on parenteral formulations. The company specialises in producing injectable drugs, including both liquid and dry powder injections, available in single-dose and multi-dose formats for human as well as veterinary use.
BMLL operates on a B2B contract manufacturing model, where it develops and manufactures formulations for other pharmaceutical companies based on their specific requirements, rather than selling directly to end consumers.
The company has its manufacturing operations in Indore and is supported by GMP and GLP certifications from the Food and Drugs Administration, Madhya Pradesh, ensuring adherence to quality and regulatory standards. It also maintains an in-house laboratory equipped with advanced testing instruments like HPLC, gas chromatography, and UV-Vis spectrophotometers for quality control and stability testing.
With a focused product portfolio, compliance-driven operations, and experienced leadership, the company aims to strengthen its position in the injectable pharmaceutical manufacturing segment.
Bio Medica Laboratories IPO Strengths & Weaknesses
Promoters bring 35+ years of combined pharma industry experience.
Diverse portfolio of 70+ injectable formulations across human and veterinary segments.
Certified manufacturing with GMP & GLP standards ensuring quality compliance.
In-house lab with advanced testing equipment supporting quality control.
Bio Medica Laboratories IPO Issue Details
| Issue Composition: | |
|---|---|
| Face Value | ₹10 per share |
| Total Issue Size | 37,72,000 shares (aggregating up to ₹2,78,000 crores) |
| Fresh Issue | 3,20,600 shares (aggregating up to ₹32,06,000 crores) |
| Offer for Sale | 37,700 shares of ₹10 (aggregating up to ₹3,77,000 crores) |
| Issue Type | Book building |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 96.84 shares |
| Post-Issue Shareholding | 67.69 shares |
Bio Medica Laboratories IPO Shares
| Minimum Shares | Maximum Shares |
|---|---|
| -- | -- |
The lot size of Bio Medica Laboratories ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Bio Medica Laboratories IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Bio Medica Laboratories IPO Contact & Registrar Details
Contact Details
Address
Plot No 11 B-11 C Sector- E Sanwer Road Industrial Area Indore
Phone Number
Website
Registrar Details
Registrar Name
Skyline Financial Services Pvt.Ltd.
Phone Number
Bio Medica Laboratories Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
| Narnolia Financial Services Ltd |
